Eprenetapopt
Eprenetapopt regimen beneficial after HSCT for TP53-mutant AML, myelodysplastic syndrome
Maintenance therapy with eprenetapopt plus azacitidine after hematopoietic stem cell transplantation led to improved survival outcomes among patients with TP53-mutant acute myeloid leukemia or myelodysplastic syndrome, study results showed.
Eprenetapopt combination improves outcomes in TP53-mutated AML, myelodysplastic syndrome
SALT LAKE CITY — Eprenetapopt plus azacitidine maintenance therapy significantly improved outcomes for patients with TP53-mutated acute myeloid leukemia and TP53-mutated myelodysplastic syndrome, according to study results.
Eprenetapopt-azacitidine regimen ‘incredibly exciting’ for TP53-mutant MDS, AML
Eprenetapopt with azacitidine exhibited encouraging activity as posttransplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia, topline data released by the agent’s manufacturer showed.
Eprenetapopt-based regimen shows promise for TP53-mutated myelodysplastic syndrome, AML
Eprenetapopt plus azacitidine appeared well-tolerated and yielded high remission rates among patients with TP53-mutated myelodysplastic syndrome and oligoblastic acute myeloid leukemia, according to results of a phase 1b/phase 2 trial.